RAVEN TAYLOR: Open Payments
NPI 1841772282 · QUEEN CREEK, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,527 in 90 payments from 18 companies in 2025. Trend: 2023 $942 · 2024 $1,308 · 2025 $1,527
Food & beverage: $1,527
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $412 |
| Novo Nordisk Inc | 14 | $257 |
| AstraZeneca Pharmaceuticals LP | 4 | $150 |
| Astellas Pharma US Inc | 6 | $134 |
| GlaxoSmithKline, LLC. | 5 | $106 |
| Lilly USA, LLC | 5 | $89 |
| PFIZER INC. | 4 | $63 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $61 |
| TOLMAR, INC. | 3 | $50 |
| Renalytix AI, Inc. | 2 | $41 |
Products named: QULIPTA, Veozah, VRAYLAR, Ozempic, FARXIGA, TRELEGY ELLIPTA, MOUNJARO, Wegovy.
Industry payments across AZ — which companies pay providers there.
